RAPAMYCIN
MODERATE
▲ +4 papers · 7d
METFORMIN
MODERATE
▲ +2 papers · 7d
GLP-1 RA
STRONG
▲ +11 papers · 7d
SENOLYTICS
EMERGING
▼ −1 retraction
NMN
EMERGING
▲ +1 RCT · 7d
ACARBOSE
MODERATE
SGLT2i
STRONG
▲ +3 meta · 30d
RAPAMYCIN
MODERATE
▲ +4 papers · 7d
METFORMIN
MODERATE
▲ +2 papers · 7d
GLP-1 RA
STRONG
▲ +11 papers · 7d
SENOLYTICS
EMERGING
▼ −1 retraction
NMN
EMERGING
▲ +1 RCT · 7d
ACARBOSE
MODERATE
SGLT2i
STRONG
▲ +3 meta · 30d
Vol.
IV
· No.
19
Thursday, May 14, 2026
Issue:
Spring · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by
PubMed
·
CTG
·
Cochrane
Editorial team ·
geroevidence.com
Subscription ·
app.geroevidence.com
Home
Interventions
Evidence
Blog
About
Pricing
Sign in
Start free trial →
Geroevidence
·
Editorial desk
·
Intervention Profiles
Intervention Profiles
Deep dives into individual longevity compounds — mechanism, evidence, trials.
3 articles in this category
·
← All categories
§ Intervention Profiles · 3 articles
Rapamycin for longevity: what the clinical evidence actually shows in 2026
A structured synthesis of every published human trial and major animal study — evidence strength rated honestly, with what is known, what is unknown, and what trials are ongoing.
May 13, 2026 · 14 min read
GLP-1 agonists beyond weight loss: the cardiovascular and longevity evidence
Semaglutide and tirzepatide are the most prescribed drugs in medicine. The weight loss story is well known. The cardiovascular and longevity evidence is more important and less understood.
May 13, 2026 · 12 min read
SGLT2 inhibitors and aging: what the evidence actually shows
Empagliflozin and dapagliflozin have some of the strongest cardiovascular and renal outcomes data in medicine. Their longevity relevance is underappreciated. Here is the evidence.
May 13, 2026 · 10 min read